Paragraph with Menu

Our community is in a relentless pursuit of therapies! 

Nutritional replacement therapies for CDG 

 

GlcNAc-PI (N-acetylglucosamine-phosphatidylinositol) is considered for the following CDG types:

  • PIGA-CDG (more information about this specific CDG type HERE, HERE and HERE)

About PIGA-CDG: is a rare and potentially devastating metabolic disorder that affects development across many systems of the body. Watch the video below and learn more about the function of PIGA in the human body, the symptoms of the disorder and potential areas of research for treatment. 

Paragraph without Menu

How can you help our CDG community? Is easy! Share among your social media and other channels the information we make available within this section and website. This raises awareness, accelerates diagnosis, and secures better care and management for our CDG children and adults!

Read A family’s global research journey searching for a treatment for PIGA-CDG, from Rare revolution Magazine.

 

What is GlcNAc-PI? 

N-acetylglucosamine-phosphatidylinositol (GlcNAc-PI) is a component of GPI-membrane anchors. These anchors help proteins sit on top of the cell membrane. GPI anchored proteins play many important roles in your body. They are responsible for ensuring that your cells do their job. 

How can it help people living with PIGA-CDG? 

The phosphatidylinositol glycan class A (shortened to PIGA protein) is part of a complex made of 7 proteins that produces GlcNAc-PI. Read more here or here). 

When one of the proteins of the complex, in this case the PIGA protein, is defective, there is a lack of GlcNAc-PI, hence by giving the GlcNAc-PI that is missing, the normal glycosylation could be restored. To better understand how GlcNAc-PI supplementation can help people living with PIGA-CDG watch this video.  

 

Publications in CDG are constantly growing. We  have selected articles of special interest for you, see below. Not all are open access, thus if you wish to  access the full information, please contact us at https://worldcdg.org/contact

Keep in mind, you are not alone. Though Congenital Disorders of Glycosylation (CDG) are categorized as “rare” there is an amazing community at your fingertips working day and night to improve the lives of many people living with CDG and their family members. We want you to know everything that is available about therapies in lay language, but we suggest you enter into it at your own pace and comfort level.

We are here to help
Should you need more details please do get in touch with our Team

Ensure that you are up to date, and join our mailing list:

 Subscribe our World CDG magazine

For further learning about CDG, move ahead to our community tailored sections across https://worldcdg.org/  

 

Didn't find what you are looking for?

Your question may help others

Authors

Vanessa Ferreira and Sandra Brasil (CDG & Allies FCT, NOVA University, World CDG Organization and Portuguese Association for CDG).  Ines Santos, Tiago Martins, Madalena Raposo from Sci and Volunteer Program Nova School of Science and Technology 2021. Ana Sofia Rodrigues (content management, CDG & Allies FCT, NOVA University, World CDG Organization and Portuguese Association for CDG).

Disclaimer

The Site cannot and does not contain medical or health advice. The information is provided for general informational and educational purposes only and is not a substitute for professional advice.

Accordingly, before taking any actions based upon such information, we encourage you to consult with the appropriate professionals. We do not provide any kind of medical or health advice. The use or reliance of any information contained on this site is solely at your own risk.

Follow Us

Like the World CDG Organization Facebook Page. Share the page on your own timeline and tell your friends to share it.
Follow us on Twitter and LinkedIn.
Subscribe to our Youtube channel and invite your friends to subscribe too.

CDG
Congenital Disorders of Glycosylation

Page modified at Monday, July 11, 2022 - 16:45